---
title: "Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298454669.md"
description: "In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Dyne Therapeutics, with a price target of $36.00. According to TipRanks, Ulz is a 3-star analyst with an average return of 3.0% and a 45.81% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alnylam Pharma, and Arrowhead Pharmaceuticals. Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $39.75."
datetime: "2026-09-09T11:55:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298454669.md)
  - [en](https://longbridge.com/en/news/298454669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298454669.md)
generator: "portal-rs"
---

# Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Dyne Therapeutics, with a price target of $36.00.

According to TipRanks, Ulz is a 3-star analyst with an average return of 3.0% and a 45.81% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alnylam Pharma, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Dyne Therapeutics is a Strong Buy with an average price target of $39.75.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy](https://longbridge.com/en/news/298319347.md)
- [Dyne Therapeutics Stock Tumbles After Hours: Here's Why](https://longbridge.com/en/news/293429148.md)
- [These Analysts Revise Their Forecasts On Texas Instruments Following Q3 Results](https://longbridge.com/en/news/302755837.md)
- [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md)
- [Western Digital Q1 Revenue Surges 55% YoY, Shares Drop Nearly 7%: Can $330 Support Hold?](https://longbridge.com/en/news/302840204.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**